atients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two coprimary endpoints — a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding — as compared to patients receiving standard anticoagulation therapy, according to a study presented at the 2015 American College of Cardiology (ACC) meeting.